ERBB2 and breast cancer: In the early BC setting, additional post-neoadjuvant treatment with T-DM1 in patients with HER2+BC who did not achieve a pCR at surgery has been shown to significantly improve both invasive disease-free survival (iDFS) and overall survival (OS).